FDA rejects Singulair-Claritin combination

Apr 30, 2008

The U.S. Food and Drug Administration rejected a proposed pill that would combine the drugs Claritin and Singular, Schering-Plough said.

The drug, a combination of loratadine and montelukast developed in a joint venture between Schering-Plough and Merck Pharmaceuticals, was targeted for patients with allergic rhinitis symptoms and nasal congestion.

The active ingredients of Claritin is loratadine and the active ingredient of Singulair is montelukast sodium. Both drugs are indicated for the relief of symptoms of seasonal allergic rhinitis and perennial allergic rhinitis, the two drug companies said in a statement.

The companies did not explain the FDA's reason for rejecting the drug combo.

Copyright 2008 by United Press International

Explore further: Novartis Japan hit with suspension over side-effect reporting

add to favorites email to friend print save as pdf

Related Stories

Asthma drug prevents spread of breast cancer: study

Nov 03, 2010

A drug commonly used in Japan and Korea to treat asthma has been found to stop the spread of breast cancer cells traditionally resistant to chemotherapy, according to a new study led by St. Michael's pathologist Dr. Gerald ...

Munich researchers discover key allergy gene

Aug 22, 2008

Together with colleagues from the Department of Dermatology and Allergy and the Center for Allergy and Environment of the Technische Universität München, scientists at the Helmholtz Zentrum München have pinpointed a major ...

Hay fever can send work productivity down the drain

Apr 26, 2007

Employers can blame hay fever for the loss of millions of hours of work productivity this spring. A new study of nearly 600 people with hay fever symptoms, including sneezing, watery eyes and runny and itchy noses, found ...

Recommended for you

Drug research and development more efficient than expected

8 hours ago

Drug R&D costs have increased substantially in recent decades, while the number of new drugs has remained fairly constant, leading to concerns about the sustainability of drug R&D and question about the factors that could ...

Use new meningitis vaccines only for outbreaks

Feb 26, 2015

(AP)—A U.S. panel on Thursday recommended that two new meningitis vaccines only be used for rare outbreaks, resisting tearful pleas to give it routinely to teens and college students.

New antibiotic avycaz approved

Feb 26, 2015

(HealthDay)—The combination antibiotic Avycaz (ceftazidime-avibactam) has been approved by the U.S. Food and Drug Administration to treat adults with complicated infections of the intra-abdominal area or urinary tract, ...

Tagging drugs to fight counterfeit medicines

Feb 25, 2015

The U.S. and other countries are enacting rules to clamp down on the sales of fake pharmaceuticals, which pose a public health threat. But figuring out a system to track and authenticate legitimate drugs still faces significant ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.